Introduction
Levetiracetam (LEV) is an antiepileptic drug with multiple mechanisms of action that correlates with his broad spectrum of activity. It inhibits neuronal hyper-synchronization, most likely by binding to synaptic vesicle protein 2a (SV2A) located in presynaptic membranes [9, 23, 43] : this is a mechanism of action related to its antiepileptic activity and which might be interesting in relation to treatment of neuropathic pain [11, 18] and dyskinesia in Parkinson disease, tardive dyskinesia, tic disorders and Huntington's disease [9] . LEV also activates the g-aminobutyric acid (GABA) and glycine system, interacts with the AMPA receptors, and partially depresses the N calcium current: all targets that have been associated with alcohol-seeking and drinking behavior [12] .
The wide broad spectrum of activity of LEV is supported by various double-blind studies that demonstrated its effectiveness and safety as add-on therapy in generalized epilepsies, such as myoclonic seizures [25] , or primary generalized tonic-clonic seizures [4] , and in partial-onset seizures [15, 31] . The FDA approved LEV as an adjunctive therapy for partial onset seizures in adults and children !4 years of age, adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents !12 years of age with juvenile myoclonic epilepsy and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children !6 years of age with idiopathic generalized epilepsy. In contrast, the EMEA approved LEV for the treatment of partial-onset seizures with or without generalization in patients from one month of age, juvenile myoclonic epilepsy in patients from 12 years of age, and of idiopathic generalized epilepsy in patients from 12 years of age.
LEV has a favorable pharmacokinetic profile that has been determined over a dose range of 500-5000 mg for adults and 20-30 mg/kg for children [11, 12] . Different randomized controlled trials (RCTs) and some meta-analyses [22, 24, 26] have shown a good safety profile for this drug. However, up to now, there are no large meta-analyses performed on all available RCTs on LEV in any condition. In fact, the existing meta-analyses separately evaluated the RCTs performed only on a specific disorder.
The aim of our study was to carry out a comprehensive metaanalysis on the safety profile of LEV using a large sample of RCTs in adults and children with regard to dose-dependent effects.
Methods

Criteria for considering studies in this review
Types of studies
We included only double-blind, placebo-controlled RCTs with parallel or crossover design that investigated the therapeutic effect of oral LEV in children and adults with various diseases. Studies performed on healthy volunteers and/or lasting less than 4 weeks were excluded. Full journal publications or summary clinical trial reports were required. Brief abstracts were excluded. Other types of studies, including non-randomized trials, case reports, or clinical observations, were not included.
Types of participants
Subjects with any age and ethnic background taking LEV for any clinical disorder, including partial or generalized epilepsy, essential tremor, multiple sclerosis, alcohol dependence, neuropathic pain, polyneuropathy, bipolar depression, social anxiety disorder, dyskinesia in Parkinson's disease. Studies on participants who underwent a concomitant drug therapy were included.
Search methods for identification of studies
In April 2013, we conducted a computer search of Medline (PubMed version), EMBASE and Cochrane library for all doubleblind placebo-controlled studies performed on LEV. Therefore, the limit ''humans'' was set and we restricted our search to articles written in English. Search strategies and a flow diagram of the selection process are available in Appendix A (Fig. A1) .
Reference lists of retrieved articles were examined and summary clinical trial reports not available as full publication were searched on the Internet in order to find additional articles. Both studies randomizing patients to a fixed or a flexible dose of LEV were selected for the purpose of this meta-analysis.
Eligibility was determined after reading each study identified by our research; two blinded reviewers independently assessed trials for inclusion in the meta-analysis. Any disagreements were resolved by discussion. Further details are provided in Appendix B.
Analysis of adverse events
Selection of adverse events
Relevant adverse events (AEs) were selected following a threestep strategy: (1) identification of synonyms (Appendix B, Table B1 ), which were grouped under one main term; (2) exclusion of rare AEs and very rare AEs (respectively from 1/10,000 to 1/1000 and less than 1/10,000, as reported by information leaflet) among those randomized to LEV or placebo (PCB); (3) exclusion of not assessable AEs, such as those reported in a single study and those not ascribable to a clear number of patients. After selecting those AEs to be included in our analyses, we extracted the frequency of each AE reported from LEV and PCB groups of each study. This information was recorded into a separate data extraction sheet.
Statistical analysis
Statistical analyses were performed using RevMan version 5.2 and IBM SPSS Statistics 19.0 [19, 57] . Statistical heterogeneity between trials was checked for each outcome using a Chi 2 test for heterogeneity. The I 2 test was also used to assess statistical heterogeneity, with an I 2 > 70% indicating heterogeneity. Where significant heterogeneity was present (only for asthenia/fatigue and dizziness at 2000 mg/day), random-effect method was used.
A fixed-effect model was used in all other outcomes showing no significant heterogeneity. The preferred estimator was the MantelHaenszel risk difference (RD). For the outcomes, 95% confidence intervals (CIs) were set. We evaluated: (1) RDs to assess the association of general tolerability (any AE), included in this analysis with LEV treatment; (2) RDs to assess the association of patients withdrawing from studies, because of AEs due to LEV; (3) RDs of 12 AEs, those described in an adequate number (>3) of included studies, in order to find which AEs were significantly associated to LEV therapy; (4) RDs to investigate dose-response relationships of LEV in term of general tolerability, withdrawal and AEs. For this latter purpose, only those studies (n = 21) in which subjects were randomized to fixed-dose regimens (1000, 2000, 3000 mg/day) were selected, since in studies allowing flexible-dose regimens (n = 4) it was not possible to assign an AE to a specific drug dose. Therefore, all children taking a flexible dose were excluded from this analysis, while adolescents (>13 y) receiving the same dosage than adults were not excluded. Given that only one included study Betts et al.
[5] adopted a drug regimen of 4000 mg/day, that could not be included in the dose-response analysis.
In order to easy interpret the dose-response relationships, each RD estimate was complemented by the computation of the number needed to harm (NNH). An inverse variance-weighted metaregression model was also applied to test the relationship between LEV dose and RDs.
Results
Included studies
Twenty-five studies (2832 participants) satisfied our inclusion criteria and were entered into our analysis (Table 1) . Twelve studies were performed with a total of 2114 epileptic patients, mainly affected by refractory partial seizures (1831, 86.6%), 283 (13.4%) with idiopathic generalized epilepsy. The remaining 13 studies were performed in 468 (22.1%) patients affected by other diseases (for more information see Appendix C). In all studies, AEs were calculated on the intention-to-treat (ITT) population. The total number of patients treated with the active drug was1698, whereas patients treated with PCB were 1329.
In two trials the participants were only children (N = 296) with an age range of 4-16 years. Thirteen studies analyzed only adults patients (N = 718, age range from 21 to 83 years). In the remaining 10 trials the study population includedboth adults and children (age range from 4 to 70 years).
The majority of trials had parallel study design, while only 7 had a crossover design.
Most trials recruited patients from USA and Europe, 2 trials recruited participants from China, 1 from Taiwan and the other studies recruited from various countries (centers in Europe, Mexico, Australia, New Zealand, USA, Canada, South Africa, India and Russia).
The treatment period included an up-titration followed by a maintenance phase in all but 2 trials, which did not include a doseup titration period. Treatment duration ranged from 2 to 24 weeks (up-titration range 4 days to 7 weeks).
LEV dosage ranged from 30 mg/kg/day to 60 mg/kg/day for children and from 500 mg/day to 4000 mg/day for adults. The trial performed by Betts et al. [5] was the only one in which a 4000 mg dose was tested.
The RCTs included in our analysis investigated the use of LEV in very different disorders, including partial (10) and generalized epilepsies (2), essential tremor (2), multiple sclerosis (1), alcohol Data for AEs were available in all studies, while data for withdrawals were lacking in 3 trials.
The minimal incidence required for each AE was set between 5 and 10%, but not all authors set a minimal percentage.
General tolerability
General tolerability was assessed by evaluating the number of patients reporting at least one AE. The overall RD for 'any AE' did not reach statistical significance (RD 0.02, 95% CI À0.02 to 0.05). When compared by dosage, a staistical significance was found only for the 3000 mg dosage (RD 0.07; 95% CI 0.01-0.12) compared to 1000 mg and 2000 mg (RD À0.01; 95% CI À0.08 to 0.06 and RD 0.18; 95% CI À0.21 to 0.56 respectively), as shown also by NNH values (Figs. 2b and 3b, Appendix B, Table B2 ).
Treatment withdrawals
The overall RD discontinuation for AEs at any age was 0.03 (95% CI 0.01-0.05); thus there was significant evidence that participants were more likely to discontinue LEV than PCB. Dose-withdrawal analysis showed a lower RD in patients taking 1000 mg (À0.01, 95% CI À0.04 to 0.03) compared to patients taking 2000 mg and 3000 mg (respectively 0.05, 95% CI 0.01 to 0.09 and 0.04, 95% CI 0.01 to 0.06). (Figs. 1, 2b and 3b) . In Fig. 2b data are reported as NNH. In the regression analysis, the risk of withdrawal due to AEs was not dose-dependent (p = 0.186).
Adverse effects
From our analysis, the AEs associated with LEV were: nasopharyngitis (RD 0.03; 95% CIs 0.00-0.06), nervousness/irritability (RD 0.06; 95% CIs 0.02-0.09); somnolence (RD 0.07; 95% CIs 0.05-0.09); asthenia/fatigue (RD 0.07; 95% CIs 0.04-0.10) and dizziness (RD 0.04; 95% CIs 0.02-0.06) (Figs. 1, 2a and 3a) .
Dose-effect correlations of statistically significant levetiracetam adverse effects
We excluded 4 studies because they use flexible-dose regimens or they provided unclear data. Therefore, the sample eligible for this analysis was represented by 21 studies, including adults and adolescents (>13 years). RDs (95% CIs) for the statistically significant LEV AEs at different doses are shown in Table 2 (see  Table B2 in appendix for more information). When grouped by dosage, statistical significance was reached only by somnolence, nervousness/irritability, and dizziness at 1000 mg/day, somnolence at 2000 mg/day, whereas all four AEs were statistically significant at LEV 3000 mg/day. A statistically significant doseresponse relationship was not found, as confirmed by the regression analyses (p = 0.134; p = 0.819; p = 0.135; p = 0.688 respectively for asthenia/fatigue, somnolence, dizziness and nervousness/irritability) and NNH values (Fig. 2a) . Nasopharyngitis did not reach statistical significance when grouped by dosage.
Discussion
Accurate analysis of AEs is essential for the optimal choice of AED, given that AEs may lead to treatment discontinuation in up to 25% of patients, and contribute to poor patient adherence [29, 30] . Several studies have shown that AEDs may remarkablydiffer for their tolerability whereas differences in efficacy are small [6] and almost impossible to assess [52] . Previous analyses aimed at assessing efficacy and tolerability of AEDs [32, 48, 52, 53] , but they failed to show a significant association between the drug and several AEs, as these studies were restricted to RCTs. Therefore, the number of recruited patients was hampered by insufficient large sample sizes to fully uncover the AE profile of a given AED.
Recent evidence, however, suggests that non-epilepsy studies can be merged with epilepsy studies in meta-analyses of RCTs of AEDs [36, 50, 54, 55] . Thus, by taking into account the little drug interaction of LEV [27] we decided to extend the target group also to non-epileptic patients. Moreover, a combined analysis of children and adults was performed in order to extend our sample. In this meta-analysis of all available RCTs of LEV, we included 2832 patients and found 5 AEs significantly associated with LEV treatment, while Mbizvo et al. [24] meta-analysis, performed on 11 trials for a total of 1861 patients identified 2 AEs significantly associated with LEV: somnolence (RR 1.58; 99% CIs 1.14-2.18) and infection (RR 1.76; 99% CIs 1.03-3.02). Furthermore, in the Mbzivo study there was insufficient evidence that participants were more likely to discontinue LEV than PCB (RR 1.03; 95% CIs 0.80-1.33). Lo et al. [22] performed another meta-analysis of 10 RCTs: the likelihood of serious AEs requiring withdrawal from the study was not significantly different between LEV patients and controls (RR = 1.37; 95% CIs 0.88-2.13). The meta-analysis of Zaccara et al. [51] was performed on 5 RCTs and found only somnolence being associated with LEV (RD 0.07; 95% CIs 0.01-0.12).
In previous meta-analyses specifically focused on the assessment of tolerability of AEDs from all RCTs, 20 AEs were significantly associated with pregabalin (PGB) in a population of almost 12.000 subjects [50] , 11 AEs were significantly associated with lacosamide (LCM) between more than 3000 patients [55] , and 5 AEs were associated with perampanel (PER) in a population of almost 4000 patients [53] , while no AEs were associated with zonisamide in a similar study performed in a more restricted population of 1184 patients [41] . Compared to Levite spectrum of the AEs observed with the other AEDs is wider for PER and PGB and narrower for LCM. Vestibulocerebellar dysfunction resulted a common effect of all these AEDs [6] .
In the current study, the 5 AEs significantly associated with LEV were: nasopharyngitis, somnolence, asthenia/fatigue, dizziness and nervousness/irritability. The association between nasopharyngitis and LEV has already been described by Mbizvo et al. [24] . Although we restricted the synonyms to upper respiratory tract infections, a possible explanation for the high frequency of nasopharyngitis may be an overlap in reporting caused by the variety of terms. Other authors suggested that the improvement in seizure control may favor socialization and consequently increase the risk of respiratory infections [7, 51] . However, the correlation between nasopharyngitis and LEV remains unclear, given that previous analyses did not show a concomitant decrease in white blood cell and neutrophil count suggesting a reduction of immunologic response to LEV [14] . Both somnolence and asthenia/fatigue may reflect the depressant CNS effect of LEV. Asthenia and fatigue might also result from decreased excitatory activity [56] . Somnolence and even more serious disturbances of vigilance and alertness are commonly impaired in individuals taking traditional AEDs [2] . Somnolence and some cognitive disturbances (confusional state, abnormal thinking, disturbance of attention) were significantly associated with PGB [50] , while somnolence was associated with PER [53] and was uncommon with LCM [55] .
A further AE associated with LEV was nervousness/irritability, which has already been reported in a previous systematic review of open label studies aimed at assessing behavioral effects of LEV in children [16] . Psychiatric effects, such as anxiety, depression and psychosis, were very rarely associated with LEV in RCTs. Only longterm observational studies provided data about an increased risk of psychiatric disorders in a subset of patients with pre-existing mood disorders [20] , likely due to a genetic predisposition [44] . These AEs are infrequent with several AEDs but significantly associated with PER [54] . Dizziness, which is a subjective AE, was the only AE related to vestibulocerebellar/brainstem dysfunction associated with LEV. Other objective and more severe AEs caused by involvement of the same brain structures (ataxia, diplopia, balance disorders, and so on) are commonly observed in individuals treated with AEDs acting on voltage-gated sodium channels, such as phenytoin, carbamazepine, lamotrigine, and oxcarbazepine [49] and have also been found significantly associated with PGB and LEV [48] .
Probably, the different spectrum of AEs linked to LEV is caused by its peculiar mechanism of action: the predominant effect of LEV on cortical function and alertness may be attributed to its action on the GABA and SV2A receptors. Moreover, the anti-epileptic actions of LEV seem to be mediated, at least partly, via the combination of inhibitory effects on depolarization-induced and Ca 2+ -induced Ca 2+ release-associated neurotransmitter releases.
An interesting finding of our meta-analysis was the unclear relationship between LEV tolerability and dose.
Specifically, LEV tolerability, measured as percentage of patients withdrawing because of AEs and as percentage of patients with any AE, showed a particular dose-relationship (see Figs. 2b  and 3 ). Whereas tolerability clearly decreased by a change in drug dose from 1000 to 2000, a further dose increment (up to 3000 mg/ d) was not associated with a worsening of tolerability. This is different from what has been observed with other AEDs, which show a clear worsening of tolerability at higher doses [53, 55] . The characteristic LEV tolerability profile was even more evident when the dose-effect relationship was analyzed for specific AEs. Only somnolence seemed to be influenced by drug dose. Strikingly, dizziness and irritability have a similar frequency at all drug doses.
Even though the reasons for these atypical findings are not clear, the lack of a dose-effect relationship for several AEs can explain the clinical profile of LEV, which is considered a drug with a very good tolerability [1, 3] and which can be titrated very fast without severe consequences [40] .
Some limitations of this meta-analysis need to be acknowledged. Firstly, RCTs have some limitations that tend to overstate the effect of a new treatment: the restrictive inclusion and exclusion criteria may lead to the enrollment of a sample notrepresentative of the target patient population. In addition, the trial relatively short observation period may underestimate longterm toxicity. Secondly, there may be demographic and clinical heterogeneity since adults and children with different disorders could receive many different concomitant therapies. Thirdly, our analysis focused on the NNH of LEV; however, it is important to take into account that clinical decisions need to weigh both harm and benefits, which were not assessed in our study. Fourthly, grouping of synonyms under one single term carries the risk of double-counting of patients, but this approach was necessary in our analysis due to the variety of terms used for AE description in RCTs. Collective efforts should be made to develop a single standardized terminology for RCTs on AEDs. Finally, our study is limited by the fact that we did not check the database for clinical studies and by a potential bias related to studies with high AEs which have beennot published.
Due to these limitations, the analysis of AEs profile of LEV requires further investigations and validation.
Conclusions
In conclusion, our results show a general good tolerability profile of LEV, which is characterized mainly by a sedative effect, reflected by somnolence and asthenia/fatigue, minimal neuropsychiatric impairment (nervousness/irritability), along with mild vestibulocerebellar manifestations, represented by dizziness, and a weak increase in upper respiratory tract infections.
Of interest, all these 5 AEs did not seem to show a clear doseresponse relationship. Further longitudinal well-conducted investigations will provide additional data on potential toxic and/or idiosyncratic effects and help in fully characterize the tolerability profile of this drug.
